Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
roche
9
×
san francisco blog main
san francisco top stories
boston blog main
boston top stories
biotech
cancer
clinical trials
national
raleigh-durham blog main
raleigh-durham top stories
indiana blog main
indiana top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
merck
amgen
blueprint medicines
bristol-myers squibb
deals
genentech
investing
keytruda
larotrectinib
What
cancer
9
×
drug
annual
clinical
fda
medical
medicines
oncology
society
approval
blueprint
conference
data
esmo
european
genetic
ipo
lung
meeting
ret
roundup
targets
today
address
advanced
ahead
ambien
american
approved
approves
arrival
asco
ash
attendees
attention
award
barcelona
bio
biotech
blood
Language
unset
Current search:
roche
×
cancer
×
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More